Literature DB >> 19918307

A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.

E Sengul1, T Eyileten, A Ozcan, M I Yilmaz, M Yenicesu.   

Abstract

IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, and currently is known to be an important cause of end stage renal disease (ESRD). Hypertension, proteinuria more than 1 g/d, and the presence of severe lesions on initial renal biopsy such as crescents and interstitial fibrosis are the most significant predictive factors for progression to ESRD. Despite its prevalence and clinical importance, there is no consensus for the treatment of patients with risk factors for a worse prognosis. Our aim is to describe here a case of crescentic IgAN, and to emphasize the effect of immunosuppressive treatment.

Entities:  

Keywords:  IgA nephropathy; crescents; immunosupression; proteinuria

Year:  2009        PMID: 19918307      PMCID: PMC2765296     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  13 in total

Review 1.  IgA nephropathy.

Authors:  Jonathan Barratt; John Feehally
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

2.  Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.

Authors:  Francis W Ballardie; Ian S D Roberts
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

3.  Corticosteroids in IgA nephropathy: a randomised controlled trial.

Authors:  C Pozzi; P G Bolasco; G B Fogazzi; S Andrulli; P Altieri; C Ponticelli; F Locatelli
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

4.  Comparative study of IgA nephropathy with and without crescents.

Authors:  C Bitencourt-Dias; M Bahiense-Oliveira; L B Saldanha; R T Barros; V Woronik
Journal:  Braz J Med Biol Res       Date:  2004-08-24       Impact factor: 2.590

5.  Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies.

Authors:  Lei-Shi Li; Zhi-Hong Liu
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

6.  Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.

Authors:  Ritsuko Katafuchi; Kiyoshi Ikeda; Tohru Mizumasa; Hiroshi Tanaka; Takashi Ando; Tetsuro Yanase; Kohsuke Masutani; Michiaki Kubo; Satoru Fujimi
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

7.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

Review 8.  Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options.

Authors:  James A Tumlin; Michael P Madaio; Randolph Hennigar
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

9.  Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.

Authors:  Ronald J Hogg; Jeannette Lee; Nancy Nardelli; Bruce A Julian; Daniel Cattran; Bryson Waldo; Robert Wyatt; J Charles Jennette; Richard Sibley; Keith Hyland; Lisa Fitzgibbons; Gladys Hirschman; James V Donadio; Bruce J Holub
Journal:  Clin J Am Soc Nephrol       Date:  2006-04-12       Impact factor: 8.237

10.  Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

Authors:  Claudio Pozzi; Simeone Andrulli; Lucia Del Vecchio; Patrizia Melis; Giovanni B Fogazzi; Paolo Altieri; Claudio Ponticelli; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

View more
  1 in total

1.  A Case Report of IgA Nephropathy Coexisting with Focal Segmental Glomerulosclerosis.

Authors:  Hassaan Iftikhar; Maryam Saleem; Anand Kaji
Journal:  Cureus       Date:  2019-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.